"""
Question: 1101 

Evidence: A total of 84 convenience samples were used for generating the experimental data presented in this study. The sequences obtained in this study were submitted to the GenBank under the accession numbers MK041550-MK041589.

Rationale: The paper explicitly states that it generated new experimental data (84 samples) and deposited new sequence accessions, indicating previously unpublished data were produced and reported.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Overall, we were successful in sequencing by NGS at least 2 of the 4/5 overlapping PCR fragments of 48 samples from our cohort included in this study. The sequences obtained in this study were submitted to the GenBank under the accession numbers MK041550-MK041589.

Rationale: The study reports sequencing results and provides GenBank accession numbers, confirming that HIV sequences were generated and reported.

Answer: Yes
"""

"""
Question: 1103 

Evidence: The patients' genomic DNA containing their HIV-1 proviruses was extracted from whole blood with the Genomic DNA Extraction Kit (Real Genomics, BioAmerica, Inc.) following manufacturer's instructions. Libraries were diluted, and pooled prior to sequencing in a MiSeq Illumina platform (2 × 301 cycles paired-end run) (Illumina) with 1% denatured PhiX DNA as a sequencing control.

Rationale: The methods describe direct extraction of proviral DNA from patient blood and NGS library preparation and sequencing; there is no mention of any in vitro virus passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: We focused on the HIV-1 subtype classification, identification of HIV recombinants and multiple infection investigation for our novel patients. Libraries were diluted, and pooled prior to sequencing in a MiSeq Illumina platform (2 × 301 cycles paired-end run) (Illumina) with 1% denatured PhiX DNA as a sequencing control.

Rationale: The study objective and methods are genomic characterization via NGS; there is no description of phenotypic susceptibility or in vitro drug testing, indicating no in vitro antiretroviral susceptibility data were reported.

Answer: No
"""

"""
Question: 2101 

Evidence: The sequences obtained in this study were submitted to the GenBank under the accession numbers MK041550-MK041589. The raw sequencing reads were deposited to the Sequence Read Archive (SRA) under the numbers SRR7993842-SRR7993872.

Rationale: The paper explicitly lists GenBank accession numbers for the sequences, confirming deposition of sequenced HIV isolates.

Answer: Yes
"""

"""
Question: 2102 

Evidence: A total of 84 convenience samples were used for generating the experimental data presented in this study. The sequences obtained in this study were submitted to the GenBank under the accession numbers MK041550-MK041589.

Rationale: The sequences are derived from clinical samples (patients), not laboratory strains, and corresponding GenBank accessions are provided.

Answer: Yes
"""

"""
Question: 2103 

Evidence: The sequences obtained in this study were submitted to the GenBank under the accession numbers MK041550-MK041589. The raw sequencing reads were deposited to the Sequence Read Archive (SRA) under the numbers SRR7993842-SRR7993872.

Rationale: The manuscript directly lists the GenBank accession range for the sequences.

Answer: MK041550–MK041589
"""

"""
Question: 2202 

Evidence: We focused on the HIV-1 subtype classification, identification of HIV recombinants and multiple infection investigation for our novel patients. Concerning the integrity of the open reading frames (ORF), 4.5% (11/247) of the sequences available in the literature, and 25% (7/28) of our sequences displayed mutations and/or insertions and deletions resulting in frameshifts or premature stop codons.

Rationale: The study does not present per-sample mutation lists; it discusses overall ORF integrity and focuses on subtype/recombination rather than enumerating mutations for individual isolates.

Answer: No
"""

"""
Question: 2301 

Evidence: Phylogenetic analysis of HIV near full-length genomes (NFLG) from this study. The great diversity of HIV-1 group M, which disseminated on a global scale and dominates the current AIDS pandemic, allowed the phylogenetic classification in nine pure subtypes (A–D, F–H, J, and K), sub-subtypes (A1–A5, F1–F2), circulating recombinant forms (CRFs) and unique recombinant forms (URFs).

Rationale: The text repeatedly specifies HIV-1, including analysis of HIV-1 near full-length genomes and group M subtypes.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: The NFLGs obtained by our group were mostly classified as HIV-1 subtype B (71%; 20/28), followed by subtype C (14%; 4/28), recombinant forms (11%; 3/28), and subtype F1 (4%; 1/28). The sequences of the 20 HIV-1 partial genomes were predominantly subtype B (7/20), C (6/20), and recombinants forms (6/20).

Rationale: These sentences list the subtypes and recombinant categories found among the sequenced viruses.

Answer: Subtype B, subtype C, subtype F1, and recombinant forms including BF1 and BC recombinants (URFs).
"""

"""
Question: 2303 

Evidence: Nested PCR performed using Platinum Taq DNA Polymerase High Fidelity was carried out ... for the amplification of HIV NFLGs. The remaining partial genome sequences had complete Gag CDS for nine samples (45%, 9/20), Pol CDS for 4 (20%, 4/20), and Env CDS for 12 (60%, 12/20).

Rationale: The study sequenced near full-length genomes; among partial sequences, complete gag, pol, and env coding sequences were obtained.

Answer: Near full-length HIV-1 genomes; gag, pol, and env genes (CDS) for partial genomes.
"""

"""
Question: 2304 

Evidence: The remaining partial genome sequences had complete Gag CDS for nine samples (45%, 9/20), Pol CDS for 4 (20%, 4/20), and Env CDS for 12 (60%, 12/20). HIV-1 consensus sequences were subjected to phylogenetic analysis to determine their subtype/CRF classification.

Rationale: The paper explicitly states that pol coding sequences were obtained for some samples and analyzed.

Answer: Yes
"""

"""
Question: 2401 

Evidence: In the pooled analysis depicted in this report, HIV subtypes have been determined from HIV-positive patients in five states of Brazil with some of the highest HIV prevalence, three in the Southeast (Rio de Janeiro, São Paulo, and Minas Gerais), one in the Northeast (Pernambuco) and one in the South (Rio Grande do Sul). Summary of the HIV-1 subtype distribution in the five Brazilian states represented in this pooled analysis (n = 350).

Rationale: The study’s sequences are from Brazil and specifically from five named Brazilian states.

Answer: Brazil (states: Rio de Janeiro, São Paulo, Minas Gerais, Pernambuco, and Rio Grande do Sul)
"""

"""
Question: 2402 

Evidence: A total of 84 convenience samples were used for generating the experimental data presented in this study. HIV-1-seropositive patients recruited between February 2016 and December 2017 during the routine services conducted at ... Hospital Federal de Ipanema (HFI) ... HU-UFRJ ... and HU-FURG.

Rationale: The recruitment period indicates when the sequenced samples were obtained for this study.

Answer: 2016–2017 (February 2016 to December 2017)
"""

"""
Question: 2502 

Evidence: Through the progress of next-generation sequencing (NGS) techniques it became possible to expand the study of HIV genetic diversity. Libraries were diluted, and pooled prior to sequencing in a MiSeq Illumina platform (2 × 301 cycles paired-end run) (Illumina) with 1% denatured PhiX DNA as a sequencing control.

Rationale: The methods describe NGS (Illumina MiSeq), not Sanger sequencing.

Answer: No
"""

"""
Question: 2503 

Evidence: Through the progress of next-generation sequencing (NGS) techniques it became possible to expand the study of HIV genetic diversity. Libraries were diluted, and pooled prior to sequencing in a MiSeq Illumina platform (2 × 301 cycles paired-end run) (Illumina) with 1% denatured PhiX DNA as a sequencing control.

Rationale: The paper explicitly used NGS (Illumina MiSeq) for sequencing.

Answer: Yes
"""

"""
Question: 2504 

Evidence: Nested PCR ... was carried out ... for the amplification of HIV NFLGs. Libraries were prepared with the Nextera XT DNA Sample Preparation kit (Illumina Inc., San Diego, United States) according to the manufacturer's protocol, except that the starting material was diluted to 0.4 ng/μL.

Rationale: The workflow used PCR amplification and tagmentation-based library prep without molecular cloning of amplicons.

Answer: No
"""

"""
Question: 2505 

Evidence: The strategies comprised the amplification of four to five fragments, from 2 to 3 kb each, spanning the whole HIV genome. Reads were assembled using an annotated HIV-1 HXB2 reference sequence and 10 iterations to obtain each viral genome sequence.

Rationale: The approach used bulk multi-amplicon NGS assemblies rather than single-genome amplification/sequencing.

Answer: No
"""

"""
Question: 2506 

Evidence: Libraries were prepared with the Nextera XT DNA Sample Preparation kit ... The library construction consists of a fragmentation step using transposon technology, followed by a PCR step where dual indexes were added to the fragments.

Rationale: The methods describe tagmentation and PCR-based indexing without any molecular cloning of viral genomes.

Answer: No
"""

"""
Question: 2601 

Evidence: The patients' genomic DNA containing their HIV-1 proviruses was extracted from whole blood ... for the amplification of HIV NFLGs. Overall, we were successful in sequencing by NGS ... samples from our cohort included in this study.

Rationale: Sequencing was performed from proviral DNA (cellular genomic DNA), not from plasma RNA.

Answer: No
"""

"""
Question: 2602 

Evidence: The patients' genomic DNA containing their HIV-1 proviruses was extracted from whole blood ... for the amplification of HIV NFLGs. A fraction of this casuistic ... We pooled these data with all Brazilian HIV-1 data comprising NFLG and partial sequences determined by NGS.

Rationale: The study specifies whole blood genomic DNA; it does not report PBMC-specific sequencing results.

Answer: No
"""

"""
Question: 2603 

Evidence: The patients' genomic DNA containing their HIV-1 proviruses was extracted from whole blood ... for the amplification of HIV NFLGs. Libraries were ... sequenced in a MiSeq Illumina platform.

Rationale: No plasma-based sequencing was performed or reported; all sequencing was from proviral DNA.

Answer: 0
"""

"""
Question: 2604 

Evidence: The patients' genomic DNA containing their HIV-1 proviruses was extracted from whole blood ... for the amplification of HIV NFLGs. Libraries were ... sequenced in a MiSeq Illumina platform.

Rationale: The study did not report PBMC-derived sequencing; it used whole blood genomic DNA.

Answer: 0
"""

"""
Question: 2605 

Evidence: The inclusion criteria were being 18 years or greater, being under first antiretroviral scheme and being upon virological success (undetectable HIV viral load) for the last 12 months. Regarding antiretroviral treatment, ... patients ... were under the HAART scheme preconized by Brazilian Ministry of Healthy.

Rationale: Participants had sustained undetectable viral loads, indicating no active viremia at sampling.

Answer: No
"""

"""
Question: 2606 

Evidence: The patients' genomic DNA containing their HIV-1 proviruses was extracted from whole blood ... for the amplification of HIV NFLGs. Nested PCR ... was carried out ... for the amplification of HIV NFLGs.

Rationale: Sequencing targeted integrated proviral DNA (reservoir) from cellular genomic DNA.

Answer: Yes
"""

"""
Question: 2701 

Evidence: The inclusion criteria were being 18 years or greater, being under first antiretroviral scheme and being upon virological success (undetectable HIV viral load) for the last 12 months. Clinical and epidemiological data were obtained through a questionnaire and 10 ml of whole peripheral blood were collected.

Rationale: Only adults (≥18 years) were included; no infants or children were sampled.

Answer: No
"""

"""
Question: 2702 

Evidence: HIV-1-seropositive patients recruited between February 2016 and December 2017 during the routine services conducted at Sexually Transmitted Diseases/HIV ambulatory at Hospital Federal de Ipanema (HFI) and at Hospital Universitário Clementino Fraga Filho (HU-UFRJ) ... and at Hospital Universitário Dr. Miguel Riet Corrêa Jr. (HU-FURG). This research was approved by the Ethics Committees in Research ...

Rationale: Recruitment occurred during routine clinical services, not as part of a clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: HIV-1-seropositive patients recruited between February 2016 and December 2017 during the routine services conducted at ... ambulatory. This research was approved by the Ethics Committees in Research ...

Rationale: As participants were recruited during routine care and not a trial, it follows that not all (indeed none) were in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: A total of 84 convenience samples were used for generating the experimental data presented in this study. Overall, we were successful in sequencing by NGS ... 48 samples from our cohort included in this study.

Rationale: Eighty-four individuals had samples collected for sequencing; of these, 48 yielded sequences.

Answer: 84
"""

"""
Question: 3102 

Evidence: A total of 84 convenience samples were used for generating the experimental data presented in this study. Overall, we were successful in sequencing by NGS ... 48 samples from our cohort included in this study.

Rationale: Only 48 of 84 samples were successfully sequenced, so not all individuals underwent successful sequencing.

Answer: No
"""

"""
Question: 4101 

Evidence: The inclusion criteria were being 18 years or greater, being under first antiretroviral scheme and being upon virological success (undetectable HIV viral load) for the last 12 months. However, it should be noted that all epidemiological HIV-1 NFLG studies based on NGS conducted in Brazil available in the literature were included in this pooled analysis.

Rationale: The newly sequenced cohort were all on ART; although pooled data included other studies, the paper does not explicitly state ART-naive status for those cohorts.

Answer: NA
"""

"""
Question: 4102 

Evidence: The inclusion criteria were being 18 years or greater, being under first antiretroviral scheme and being upon virological success (undetectable HIV viral load) for the last 12 months. Regarding antiretroviral treatment, 19 patients from HI (19/32, 59%), four patients from HU-UFRJ (4/12, 33%), and 23 patients from HU-FURG (23/40, 58%), were under the HAART scheme preconized by Brazilian Ministry of Healthy at the time of sample collection, composed of tenofovir (TDF), lamivudine (3TC), and efavirenz (EFV).

Rationale: The study’s newly sequenced individuals were actively receiving ART regimens, indicating ART-experienced sequences were reported.

Answer: Yes
"""

"""
Question: 4103 

Evidence: The inclusion criteria were being 18 years or greater, being under first antiretroviral scheme and being upon virological success (undetectable HIV viral load) for the last 12 months. Regarding antiretroviral treatment, ... patients ... were under the HAART scheme ... composed of tenofovir (TDF), lamivudine (3TC), and efavirenz (EFV).

Rationale: The sequences generated by this study were from ART-experienced individuals; the paper does not report sequences from ART-naive individuals within its new data.

Answer: No
"""

"""
Question: 4104 

Evidence: The inclusion criteria were being 18 years or greater, being under first antiretroviral scheme and being upon virological success (undetectable HIV viral load) for the last 12 months. All schemes used by the patients are described in Table 2.

Rationale: Since all newly sequenced participants were on their first ART scheme, none were ART-naive at sampling.

Answer: 0
"""

"""
Question: 4105 

Evidence: All schemes used by the patients are described in Table 2. The inclusion criteria were being ... under first antiretroviral scheme ...

Rationale: The paper provides current regimen information for the newly sequenced individuals but not complete ART histories for all individuals in the overall study (including pooled external datasets), and it does not detail prior regimen changes beyond stating first-line.

Answer: No
"""

"""
Question: 4201 

Evidence: We focused on the HIV-1 subtype classification, identification of HIV recombinants and multiple infection investigation for our novel patients. The analysis of all Brazilian HIV-1 NFLG obtained by NGS give us a more accurate evaluation of the viral diversity present in this epidemic.

Rationale: The study centers on genetic diversity, subtypes, and recombination; it does not analyze or report transmitted drug resistance prevalence.

Answer: No
"""

"""
Question: 4202 

Evidence: We focused on the HIV-1 subtype classification, identification of HIV recombinants and multiple infection investigation for our novel patients. The analysis of all Brazilian HIV-1 NFLG obtained by NGS give us a more accurate evaluation of the viral diversity present in this epidemic.

Rationale: The paper does not evaluate pretreatment drug resistance; its focus is on subtypes and recombination.

Answer: No
"""

"""
Question: 4301 

Evidence: Regarding antiretroviral treatment, 19 patients from HI ... four patients from HU-UFRJ ... and 23 patients from HU-FURG ..., were under the HAART scheme ... composed of tenofovir (TDF), lamivudine (3TC), and efavirenz (EFV). All schemes used by the patients are described in Table 2.

Rationale: The regimens include NRTIs (TDF, 3TC, AZT, FTC), an NNRTI (EFV or NVP), and various boosted PIs (e.g., ATV/r, LPV/r, FPV/r, DRV/r) as shown in Table 2.

Answer: NRTIs, NNRTIs, and protease inhibitors (boosted PIs)
"""

"""
Question: 4302 

Evidence: Regarding antiretroviral treatment, ... were under the HAART scheme preconized ... composed of tenofovir (TDF), lamivudine (3TC), and efavirenz (EFV). All schemes used by the patients are described in Table 2.

Rationale: Reported regimens include NRTIs, NNRTIs, and PIs; there is no mention of integrase inhibitors.

Answer: No
"""

"""
Question: 4303 

Evidence: All schemes used by the patients are described in Table 2. Regarding antiretroviral treatment, ... were under the HAART scheme ... composed of tenofovir (TDF), lamivudine (3TC), and efavirenz (EFV).

Rationale: Table 2 shows multiple PI-containing regimens (e.g., ATV/r, LPV/r, FPV/r, DRV/r), indicating that the paper reports information on individuals who received PIs.

Answer: Yes
"""

"""
Question: 4304 

Evidence: All schemes used by the patients are described in Table 2. Regarding antiretroviral treatment, ... were under the HAART scheme ... composed of tenofovir (TDF), lamivudine (3TC), and efavirenz (EFV).

Rationale: Multiple different regimens are listed in Table 2 (NNRTI-based and PI-based), so not all individuals received the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: Regarding antiretroviral treatment, ... were under the HAART scheme ... composed of tenofovir (TDF), lamivudine (3TC), and efavirenz (EFV). All schemes used by the patients are described in Table 2.

Rationale: No integrase inhibitor–containing regimens are reported; thus, individuals are INSTI-naive.

Answer: Yes
"""

"""
Question: 4403 

Evidence: The inclusion criteria were being ... under first antiretroviral scheme ... All schemes used by the patients are described in Table 2.

Rationale: Because inclusion required being on the first ART regimen, no individual had received more than one ART regimen.

Answer: 0
"""

"""
Question: 4404 

Evidence: The inclusion criteria were being ... under first antiretroviral scheme ... All schemes used by the patients are described in Table 2.

Rationale: As all were on their first regimen, none had more than two regimens.

Answer: 0
"""

"""
Question: 4405 

Evidence: The inclusion criteria were being ... under first antiretroviral scheme ... All schemes used by the patients are described in Table 2.

Rationale: The inclusion criteria imply each individual had exactly one regimen at the time point, so they all had the same number of regimens.

Answer: Yes
"""

"""
Question: 4406 

Evidence: The inclusion criteria were being ... under first antiretroviral scheme ... All schemes used by the patients are described in Table 2.

Rationale: Being on the first regimen indicates each individual had one ART regimen.

Answer: Yes
"""

"""
Question: 4501 

Evidence: Regarding antiretroviral treatment, ... were under the HAART scheme ... composed of tenofovir (TDF), lamivudine (3TC), and efavirenz (EFV). All schemes used by the patients are described in Table 2.

Rationale: The regimens listed do not include dolutegravir; therefore, no individuals received dolutegravir.

Answer: 0
"""

"""
Question: 4502 

Evidence: All schemes used by the patients are described in Table 2. Regarding antiretroviral treatment, ... were under the HAART scheme ... composed of tenofovir (TDF), lamivudine (3TC), and efavirenz (EFV).

Rationale: Table 2 shows one subject on DRV/r (darunavir/ritonavir), indicating a single individual received darunavir.

Answer: 1
"""

"""
Question: 5101 

Evidence: We focused on the HIV-1 subtype classification, identification of HIV recombinants and multiple infection investigation for our novel patients. Concerning the integrity of the open reading frames (ORF), ... our sequences displayed mutations and/or insertions and deletions resulting in frameshifts or premature stop codons.

Rationale: The paper does not analyze or report drug resistance mutations per individual; it discusses ORF integrity and recombination, not DRM prevalence.

Answer: NA
"""

"""
Question: 5102 

Evidence: We focused on the HIV-1 subtype classification, identification of HIV recombinants and multiple infection investigation for our novel patients. The analysis of all Brazilian HIV-1 NFLG obtained by NGS give us a more accurate evaluation of the viral diversity present in this epidemic.

Rationale: No analysis of integrase inhibitor resistance mutations is presented.

Answer: NA
"""

"""
Question: 5103 

Evidence: We focused on the HIV-1 subtype classification, identification of HIV recombinants and multiple infection investigation for our novel patients. The analysis of all Brazilian HIV-1 NFLG obtained by NGS give us a more accurate evaluation of the viral diversity present in this epidemic.

Rationale: The study does not report TDF-associated resistance mutations.

Answer: NA
"""

"""
Question: 5104 

Evidence: We focused on the HIV-1 subtype classification, identification of HIV recombinants and multiple infection investigation for our novel patients. The analysis of all Brazilian HIV-1 NFLG obtained by NGS give us a more accurate evaluation of the viral diversity present in this epidemic.

Rationale: No INSTI resistance mutations are reported; therefore, none can be listed.

Answer: NA
"""

"""
Question: 6101 

Evidence: Libraries were diluted, and pooled prior to sequencing in a MiSeq Illumina platform (2 × 301 cycles paired-end run) (Illumina) with 1% denatured PhiX DNA as a sequencing control. We focused on the HIV-1 subtype classification, identification of HIV recombinants and multiple infection investigation for our novel patients.

Rationale: The paper describes only genomic sequencing and analyses; no phenotypic susceptibility testing method is reported.

Answer: NA
"""

"""
Question: 6102 

Evidence: We focused on the HIV-1 subtype classification, identification of HIV recombinants and multiple infection investigation for our novel patients. Libraries were ... sequenced in a MiSeq Illumina platform.

Rationale: There are no IC50 or IC90 values presented.

Answer: No
"""

"""
Question: 6103 

Evidence: We focused on the HIV-1 subtype classification, identification of HIV recombinants and multiple infection investigation for our novel patients. Libraries were ... sequenced in a MiSeq Illumina platform.

Rationale: The study does not include phenotypic assays; thus, no IC50 fold-change data are reported.

Answer: No
"""

"""
Question: 6104 

Evidence: We focused on the HIV-1 subtype classification, identification of HIV recombinants and multiple infection investigation for our novel patients. Libraries were ... sequenced in a MiSeq Illumina platform.

Rationale: No phenotypic susceptibility assay was used or described.

Answer: NA
"""

"""
Question: 6105 

Evidence: We focused on the HIV-1 subtype classification, identification of HIV recombinants and multiple infection investigation for our novel patients. The analysis of all Brazilian HIV-1 NFLG obtained by NGS give us a more accurate evaluation of the viral diversity present in this epidemic.

Rationale: Replication capacity measurements are not reported.

Answer: No
"""

"""
Question: 6106 

Evidence: We focused on the HIV-1 subtype classification, identification of HIV recombinants and multiple infection investigation for our novel patients. Libraries were ... sequenced in a MiSeq Illumina platform.

Rationale: No phenotypic drug susceptibility testing was performed; hence, no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: The patients' genomic DNA containing their HIV-1 proviruses was extracted from whole blood ... for the amplification of HIV NFLGs. The sequences obtained in this study were submitted to the GenBank under the accession numbers MK041550-MK041589.

Rationale: Sequences were derived from patient samples and not from site-directed mutagenesis constructs.

Answer: No
"""

"""
Question: 7102 

Evidence: The patients' genomic DNA containing their HIV-1 proviruses was extracted from whole blood ... for the amplification of HIV NFLGs. Libraries were diluted, and pooled prior to sequencing in a MiSeq Illumina platform (2 × 301 cycles paired-end run) (Illumina) with 1% denatured PhiX DNA as a sequencing control.

Rationale: The workflow did not include in vitro passage; it involved direct amplification and sequencing of proviral DNA.

Answer: No
"""